| answer text |
<p>The importance of antibodies to SARS-CoV-2 is recognised in the search for effective
treatments for COVID-19 infection. At present there are a range of clinical trial
initiatives in the United Kingdom in which treatments are being carefully evaluated,
including. Some known sources of antibodies to SARS-CoV-2. The REMAP-CAP clinical
trial involves two sites at which plasma from patients who are convalescing after
COVID-19 infection are being clinically evaluated. Plasma is collected at least 28
days after recovery so that antibody levels have increased significantly.</p><p>Other
initiatives are bringing forward candidate treatments that, although promising, cannot
be immediately deployed as they will require further research before they can be safely
evaluated in human trials. Alternative sources of antibodies, such as the source described
in this publication, may be in scope for consideration if other approaches fail.</p>
|
 |
